Head to Head Survey: Astrana Health (NASDAQ:ASTH) versus biote (NASDAQ:BTMD)

biote (NASDAQ:BTMD – Get Free Report) and Astrana Health (NASDAQ:ASTH – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for biote and Astrana Health, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
biote 1 1 1 1 2.50
Astrana Health 0 2 8 0 2.80

biote currently has a consensus price target of $2.50, suggesting a potential upside of 182.17%. Astrana Health has a consensus price target of $50.38, suggesting a potential upside of 69.90%. Given biote’s higher probable upside, equities analysts clearly believe biote is more favorable than Astrana Health.

Profitability

This table compares biote and Astrana Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
biote -1.08% -8.61% 4.61%
Astrana Health 1.36% 11.57% 4.17%

Valuation & Earnings

This table compares biote and Astrana Health”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
biote $192.22 million 0.17 $27.05 million ($0.10) -8.86
Astrana Health $3.18 billion 0.52 $22.49 million $1.07 27.71

biote has higher earnings, but lower revenue than Astrana Health. biote is trading at a lower price-to-earnings ratio than Astrana Health, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

21.7% of biote shares are held by institutional investors. Comparatively, 52.8% of Astrana Health shares are held by institutional investors. 32.4% of biote shares are held by insiders. Comparatively, 20.3% of Astrana Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

biote has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Comparatively, Astrana Health has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Summary

Astrana Health beats biote on 9 of the 15 factors compared between the two stocks.

About biote

(Get Free Report)

Biote is a medical technology and services company focused on hormone optimization. It supports healthcare providers who offer bioidentical hormone replacement therapy (BHRT), including pellet-based treatment programs for eligible patients. The company’s services include provider training and education, patient and practice support, and hormone testing and treatment protocols. Biote also offers nutritional supplements and related wellness products through participating providers. Biote was founded in 2012 and serves a network of healthcare providers in the United States.

About Astrana Health

(Get Free Report)

Astrana Health, Inc. is a physician-centric healthcare company that coordinates and delivers care through a network of primary care physicians, specialists and other providers. Its services include primary and specialty care, care coordination, hospital-based care and technology-enabled population health management. The company works with health plans and provider groups under value-based care arrangements, which emphasize coordinating care and managing patients’ health needs across different settings.

Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.